stride study semaglutide STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients STRIDE - Semaglutide and walking
Description
The most common side effects observed in phase 2 clinical trials were gastrointestinal-related
Because GLP-1 drugs frequently result in muscle mass and body fat loss, it is critical to compensate as much as possible by ingesting protein
Skeletal muscle is recognized as an essential marker for metabolic health and energy requirements
18 World Health Organization
Molecules 28 , 2982 (2023)
